

I'm not a robot



Hives, or urticaria, are raised, often itchy welts or bumps. They appear when a trigger in the body (sometimes known and other times unknown) causes mast cells in the skin to release high levels of histamine, serotonin, or some other chemicals. When hives are present for more than six weeks without a known cause, the condition is called chronic idiopathic urticaria (CIU). This article will discuss chronic idiopathic urticaria, including its causes, diagnosis, treatment, and when to see a healthcare provider. Chronic idiopathic urticaria is characterized by the appearance of hives—skin-colored welts or raised patches (angioedema)—that last for six or more weeks for no known reason. This condition is also called chronic spontaneous urticaria. The exact cause of chronic idiopathic urticaria is unknown, which can make getting a diagnosis frustrating and difficult. Some research points to an altered gut microbiome (the balance of bacteria in your intestines) as a possible cause. This theory is based on the gut microbiome's important role in the function and regulation of the immune system. But more research needs to be done to determine the causal relationship between the two. Known causes of urticaria, like systemic conditions (diabetes, hyperthyroidism, cancer), viral infection (hepatitis and herpes zoster infection), and bacterial infection (Helicobacter pylori), among others, must be ruled out in order before a diagnosis of CIU can be made. CIU is a diagnosis of exclusion, meaning other causes must be ruled out before making this diagnosis. Therefore, the diagnosis of CIU may involve an extensive workup to look for the underlying conditions that serve as a potential trigger of the disease. Chronic idiopathic urticaria is a clinical diagnosis based on your symptoms using the following five criteria: Symptoms: These include the presence of intensely itchy hives, with well-circumscribed, raised welts. Associated symptoms such as pain and burning may also be present. Medical history: A medical history specifically focuses on your allergies, contact with foreign substances and occupational hazards, past medical conditions, and the medications you are taking. Physical examination:Duration: Symptoms have been experienced for six or more weeks.No specific or identifiable cause:No particular labs or tests need to be performed unless your medical history or physical examination detects specific underlying conditions as the cause of your symptoms. The healthcare providers most commonly making this diagnosis are primary care physicians or dermatologists (specialists in diseases of the skin, hair, and nails). Chronic urticaria is usually benign and, in some cases, may resolve on its own without the need for treatment. If there are triggers that you and your healthcare provider identify as potential causes, such as contact with a foreign substance or occupational exposure, these should be avoided. Symptom management with medication is the mainstay of treatment. Chronic hives can cause significant discomfort, greatly affecting your quality of life. Medication may be considered to lessen the severity and duration of symptoms. Histamine receptor blockers, namely second-generation H1 antihistamines such as Zyrtec (cetirizine), Xyzal (levocetirizine), and Claritin (loratadine) are first-line drugs for the condition. You can purchase these over-the-counter (OTC) at your local pharmacy, although your healthcare provider often prescribes these medications with specific instructions on how to take them. They are also usually covered by your insurance. Generally, your healthcare provider will prescribe the lowest, most effective dose possible. Over time, higher doses of the same or new medications may be prescribed if your symptoms have not improved. If second-generation H1 antihistamines are not effective, one or more drugs from the following drug classes may be prescribed instead: First-generation H1 antihistamines such as Benadryl (diphenhydramine) H2 blockers such as Pepcid (famotidine) and Tagamet (cimetidine) Leukotriene receptor antagonists like Acolate (zafirlukast) and Singulair (montelukast) Xolair (omalizumab) or cyclosporine (may be used in cases that don't respond to antihistamines) If you're itching is accompanied by any of the following symptoms, you should seek immediate medical attention. These may be signs of early anaphylactic shock (a life-threatening allergic reaction) or the presence of an underlying medical condition: FeverChillsShortness of breathSwelling of the tongue, mouth, lips, or throatChest/abdominal symptoms such as nausea, vomiting, stomach cramps, or diarrheaChronic idiopathic urticaria is the appearance of persistent hives that lasts for six or more weeks for no known reason. CIU is a diagnosis of exclusion, which means other causes must be ruled out before this diagnosis is made. Therefore, the diagnosis of CIU may involve an extensive workup looking for potential triggers of the disease. Hives usually go away on their own. When they last for six or more weeks, however, they may indicate an underlying medical condition requiring further medical evaluation. If your symptoms do not, change with conventional first-line treatments over the course of two weeks, follow up with your healthcare provider. They can evaluate you and direct you to the proper subspecialist who can look for the potential causes behind your hives. Frequently Asked Questions Hives that don't go away may indicate CIU or the presence of a number of underlying conditions, but a full workup is needed to uncover the possible causes of your hives. The following conditions may have a similar appearance to hives and may be mistaken for urticaria: contact dermatitis, eczema (atopic dermatitis), psoriasis, rosacea, and pityriasis rosea. CIU often resolves on its own, although symptomatic treatment may be helpful. There are no medications or lifestyle modifications that cure CIU. Hives typically last for less than two weeks. A diagnosis of CIU can only be made if your hives are present for six or more weeks. Hives are raised red bumps (welts) or spotsches on the skin. They're a type of swelling on the surface of your skin and happen when your body has an allergic reaction. Allergic reactions happen when your immune system comes in contact with an allergen. Allergens are proteins that are harmless to many people but cause an allergic reaction in sensitive people.Hives are often very itchy, but you might also feel burning or stinging. They can be as small as a fingertip or as big as a dinner plate. The medical name for hives is urticaria.Sometimes, the welts from hives join together to form larger areas called plaques. Hives typically fade away within 24 hours, although they may not be noticeable for several days or longer.Types of hivesAcute urticaria refers to hives that do not last very long (less than six weeks). Chronic urticaria refers to hives that last for more than six weeks.Chronic, spontaneous urticaria is the name for chronic hives that don't have an obvious cause. An older name for this condition is chronic idiopathic urticaria.This is also a condition called physical urticaria, or inducible urticaria. These hives might pop up when you're in the heat, hold or sun. Some people react to vibrations or pressure, exercising or sweating. Physical hives usually appear within an hour after exposure. This type of hives can also be chronic.What's the difference between hives and a rash?A rash is a skin condition that involves something out of the ordinary, like spots, swelling, itchiness or redness. Hives are an example of a rash, but not all rashes are hives.Hives: Who is affected by hives?Anyone can get hives. If you're someone who reacts to many types of allergens, you may get hives frequently. Other people who don't react to allergens may get hives once or a few times in their lives.There seems to be a relationship between acute hives and conditions like asthma, allergic rhinitis and atopic dermatitis, especially in children. You might also be affected by hives during periods of extreme stress.How common are hives?Around 20% of the population will have hives at least one time. About 1% to 3% of the population has chronic hives. Medication class that inhibits leukotriene synthesis and/or activityAntileukotrienesDrug classIdentifierSynonymsLeukotriene modifiers: Leukotriene receptor antagonistsMechanism of action • Enzyme inhibition • Receptor antagonismBiological target • Enzymes: 5-LOX; FLAP • Receptors: CysLTRsLeuk statulin Wikidata An antileukotriene, also known as leukotriene modifier and leukotriene receptor antagonist, is a medication which functions as a leukotriene-related enzyme inhibitor (arachidonate 5-lipoxygenase) or leukotriene receptor antagonist (cysteinyl leukotriene receptors) and consequently opposes the function of these inflammatory mediators: leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5-lipoxygenase activating protein (FLAP) inhibit functioning of 5-lipoxygenase and may help in treating atherosclerosis.[9] Examples of 5-LOX inhibitors include drugs, such as meclofenamate sodium[10] and zileuton.[10][3] Some chemicals found in trace amounts in food, and some dietary supplements, also have been shown to inhibit 5-LOX, such as baicalein.[10] caffeic acid,[10] curcumin,[10] hyperforin[4][5][6] and St John's wort.[4][5][6] Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle via receptor antagonism.[citation needed] These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil count in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti-inflammatory properties.[citation needed] Antihistamine " a b c Scott JP, Peters-Golden M (September 2013). "Antileukotriene agents for the treatment of lung disease". *Am. J. Respir. Crit. Care Med.* **188** (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826. Singh, Rakesh Kumar; Tandon, Ruchi; Dasidhar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". *Journal of Asthma*. **50** (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232. S2CID 11433313. ^ a b "Zyrlo (Zileuton tablets)" (PDF). United States Food and Drug Administration. Cornerstone Therapeutics Inc. June 2, 2012. p. 1. Retrieved 12 December 2014. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTB5, and LTC4) formation. (LTB4) and LTC4 are potent mediators of inflammation, leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and vascular secretion in asthma and other allergic conditions. Leukotriene-related antagonists, such as montelukast, zafirlukast, and pranlukast, are used to treat asthma and allergic rhinitis. Leukotriene receptor antagonists are sometimes colloquially referred to as leukotriene blockers. Leukotriene receptor antagonists, like zileuton and Hyaluronidase, inhibit the synthesis of leukotrienes. [3][4][5][6] can be used to treat these diseases. [1] They are less effective than corticosteroids for treating asthma. [7] But more effective for treating certain mast cell disorders.[8] There are two main approaches to block the action of leukotrienes. [1] Main article: Arachidonate 5-lipoxygenase inhibitor Drugs that inhibit the leukotriene 5-lipoxygenase pathway of leukotriene metabolism.[3][4] drugs such as MK-886 that block the 5

